AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02642796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electric nerve stimulation
Description: The TENS device will be applied for treatment periods of 30-40 minutes. The electrodes will be connected to the TENS device are stimulated in modulation mode and the parameters will be adjusted as pulse width of 60 μs,frequency of 120 Hz and the stimulation intensity as high as the subject could tolerate.~Electrodes will be placed on either lumbar and sciatic nerve tracing unilaterally or on either side or parallel to the surgical wound.
Study NCT02763072 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enlighten Laser
Study NCT02763072 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Excel V Laser
Study NCT03282968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REWIRE
Description: First, the patient will play the Fruit Catcher (weight transfer) game on the 3rd level for 3 minutes, followed by 3 minutes of rest. Next, the patient will play the Horse Runner (squats) on the 3rd level for 3 minutes, followed by 3 minutes of rest. In the end, the patient will play the Animal Hurdler (standing on one leg) on the 3rd level for 3 minutes. During the games, the patient will be standing on the Wii Balance Board, holding to a firm support if necessary. During the rest periods, the patients will be sitting. A physiotherapist will be present throughout the exercise for safety and help if requested.
Study NCT03282968 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance exercises
Description: The patient will first practice balance transfer for 3 minutes (standing by a ladder, holding position on each leg for 3 seconds), followed by 3 minutes of rest. Next, the patient will be performing squats for 3 minutes, followed by 3 minutes of rest. In the end, the patient will practice alternatively lifting lower limbs (like stepping on a footstool) for 3 minutes. During the rest periods, the patients will be sitting. A physiotherapist will be present throughout the exercise for safety and help if requested.
Study NCT00506818 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multifactorial vascular-risk-factor-intervention
Study NCT00836017 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No intervention was administered as part of the study.
Study NCT02235220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Composite resin restoration
Description: Masticatory muscular activity is measured before and after treatment with additive composite resin fillings (Tetric EvoCeram, Ivoclar Vivadent, Schaan, Liechtenstein). A Grindcare (Medotech A/S, Herlev, Denmark) device is used for determination of muscular activity.~A first measurement is conducted, followed by 4 weeks without any intervention. A second measurement is then carried out before restoration of the canine cusps with composite fillings. A third measurement is conducted, again followed by 4 weeks without any intervention. At last a final measurement is conducted.
Study NCT01701037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabrafenib
Description: 150 mg given PO
Study NCT01701037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trametinib
Description: 2 mg given PO
Study NCT01701037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02442271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
Study NCT02442271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Tablet
Study NCT01349101 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Myeloablative HSCT Arm: Total body irradiation (TBI) is given in 8 fractions over 4 days (total dose of 12 Gy)~Reduced Intensity HSCT Arm: TBI is given in one fraction (total dose of 2 Gy)
Study NCT01349101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is administered on the third day after the hematopoietic stem cell transplantation (HSCT) to help reduce graft-versus-host disease (GVHD). It is given at a dose of 60 mg/kg/d for 2 days on days +3 and +4.
Study NCT01349101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Started the fifth day after the transplant to help prevent graft-versus-host disease (GVHD).
Study NCT01349101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Started the fifth day after the transplant to help prevent graft-versus-host disease (GVHD).
Study NCT01349101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Started the fifth day before the transplant. Given for four days at 30 mg/m2/d.
Study NCT01349101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Started the fourth day before the transplant. Given for two days at 3.2 mg/kg.
Study NCT01349101 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: Allogeneic marrow transplantation given after the last dose of total body irradiation (TBI)
Study NCT02777515 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: using electronic cigarette
Description: Assesment of patients, using electronic cigarette, presenting to the Rhythm of consultation for a cardiovascular evaluation by:~1. A compendium of history, a general physical examination (weight, height) and cardiovascular with measurement of oxygen saturation, an assessment of past and current smoking (with documentation of the concentration of nicotine in the electronic cigarette and the product brand used)~2. measurement of blood pressure~3. An electrocardiogram~4. A Holter-ECG 10 minutes~5. A transthoracic echocardiogram
Study NCT04420338 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: rapid serological tests carried out
Study NCT04420338 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Serum tube collection
Description: SARS-COV2 seroconversion assay
Study NCT00522340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Program
Description: Home walking 1 hour a day for 5 days/week for 8 weeks. Then 30 minutes a day on all or most days of the week.
Study NCT01575717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 4000 IU
Description: Participants with serum 25-hydroxyvitamin D levels of less than or equal to 15ng/ml will take 4000 IU of vitamin D3 daily by mouth for 6 months
Study NCT01575717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 2000 IU
Description: Participants with serum 25-hydroxyvitamin D levels of greater than 15 ng/ml and less than or equal to 25ng/ml will take 2000 IU of vitamin D3 daily by mouth for 6 months
Study NCT04606836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: See group descriptions
Study NCT02126930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharma consult
Description: Upon hospital discharge, patients randomized to the experimental arm will have a pharmaceutical consultation concerning their anti-infectious treatment.
Study NCT02108210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Study NCT02108210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02613546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: The study group will undergo 10 sessions of guidelines and cognitive behavioral therapy (CBT) about an hour long, once a week. Of these:~1. evaluation session;~2. sessions of psychoeducation about the CBT model~5 sessions of cognitive restructuring 2 sessions of preventing relapse
Study NCT00961038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), placebo will be given twice daily, with a concluding single dose (on day 12)
Study NCT02613546 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control therapy
Description: The control group will be subjected to 10 weekly sessions (1 time per week) approximately one hour guidelines.
Study NCT01612169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN) Group
Description: The patient navigator approach includes five functions: 1) establishing an effective working relationship; 2) encouraging identification and use of strengths, abilities and assets; 3) supporting client control over goal setting and the search for needed resources; 4) viewing the community as a resource and identifying informal sources of support; and 5) conducting case management as an active community based activity.
Study NCT01612169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigator Plus Contingency Management (PN+CM) Group
Description: Study participants randomized to this group will receive the patient navigation (PN) intervention as outlined above combined with contingency management (CM).
Study NCT00457743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib malate (SU011248)
Description: SU011248
Study NCT02933944 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG02-treatment
Study NCT00609219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous EBV specific CTLs
Description: 30-40cc of peripheral blood will be used to generate EBV specific CTLs~Group One:~Day 0 - 2 x 10\^7 cells/m2 Day 14 - 2 x 10\^7 cells/m2~Group Two:~Day 0 - 2 x 10\^7 cells/m2 Day 14 - 1 x 10\^8 cells/m2~Group Three:~Day 0 - 1 x 10\^8 cells/m2 Day 14 - 2 x 10\^8 cells/m2
Study NCT04237740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: relenvatinib
Description: The enrolled patients are treated with lenvatinib (dose: body weight \< 60 kg: 8 mg/day, body weight ≥ 60 kg 12 mg/day).
Study NCT01486784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birinapant
Description: IV formulation to be given weekly 3 weeks out of 4 week cycle or 4 weeks our of a 4 week cycle as a 30 minute infusion
Study NCT02297542 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flu Vaccine
Study NCT04426838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBTi) via Videoconference
Description: The CBTi protocol will include stimulus control, sleep compression, relaxation, sleep hygiene, and cognitive restructuring which will be done over 4 weeks with one session weekly delivered via videoconference.
Study NCT04093258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Total 1® Multifocal Contact Lenses
Description: TEST
Study NCT04093258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air Optix® Multifocal Contact Lenses Plus HydraGlyde®
Description: CONTROL
Study NCT01017809 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aprepitant
Description: Cycle 1, day 2 to 17: Emend 80mg once daily in the morning on days 2 through 17 Cycles 2-6 (optional extension arm): same Emend dosing
Study NCT02126930 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Patients randomized to this arm will receive care in the habitual manner.
Study NCT03907800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 125 mg/m² weekly, infusion, 3 weeks on 1 week off, applicated for four cycles.
Study NCT05130073 — intervention group
Intervention type: PROCEDURE
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT02899117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: There are 4 yoga sessions completed with a certified instructor during cancer treatment
Study NCT05130073 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records
Study NCT05130073 — intervention group
Intervention type: PROCEDURE
Intervention: Follow-Up
Description: Undergo follow-up
Study NCT05130073 — intervention group
Intervention type: PROCEDURE
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT00660218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel poliglumex
Description: Phase I: 40 mg/m2 IV weekly in Cohort 1 (first 3 subjects), escalating in increments of 10 mg/m2 for Cohorts 2 through 5 (3 subjects each) until the maximum tolerated dose (up to 80 mg/m2 IV weekly) is established; Phase II: MTD mg/m2 IV weekly as established in Phase I (24 additional subjects)
Study NCT00660218 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 400 mg/m2 IV loading dose one week prior to starting other study treatments, then 250 mg/m2 IV weekly on same day as paclitaxel poliglumex
Study NCT00660218 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy (IMRT or 3D-CRT)
Description: radiation therapy to the head and neck, consisting of 33 daily fractions of 2.12 Gy for a total of 69.96 Gy, to begin the same day as paclitaxel poliglumex
Study NCT03156218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modulation of FiO2
Description: Modulation of FiO2: FiO2 will be reduced to 21% or until peripheral oxygen saturation of 92%, whatever occurs first. Subsequently FiO2 will be increased up to 100%.
Study NCT04350684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umifenovir
Description: This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Umifenovir in COVID-19 patients.
Study NCT00661349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: 2 ITIAN (o 1 ITIAN+TDF)+ lopinavir/ritonavir, 2 tablet 200/50 mg to 12 hours
Study NCT04350684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon-β 1a
Description: This Drug will be used in all arms as we discovered its benefits in our previous randomized clinical trial.
Study NCT04350684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-β 1a
Description: This Drug will be used in all arms as we discovered its benefits in our previous randomized clinical trial.
Study NCT04350684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir / Ritonavir
Description: This Drug will be used in all arms as mandated by our governmental guidelines.
Study NCT04350684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir / Ritonavir
Description: This Drug will be used in all arms as mandated by our governmental guidelines.
Study NCT04350684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single Dose of Hydroxychloroquine
Description: This Drug will be used in all arms as mandated by our governmental guidelines.
Study NCT04350684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Dose of Hydroxychloroquine
Description: This Drug will be used in all arms as mandated by our governmental guidelines.
Study NCT04350684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standards of Care
Description: This Drug will be used in all arms as mandated by our governmental guidelines.
Study NCT04350684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standards of Care
Description: This Drug will be used in all arms as mandated by our governmental guidelines.
Study NCT04052061 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 t-haNK
Description: CD19 t-haNK Suspension for Infusion
Study NCT04505488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASD Screening Parent ENgagement Intervention Program (ASPEN)
Description: The ASPEN intervention is based on naturalistic developmental behavioral intervention strategies to support the development of social communication and play skills and reduce challenging behavior.
Study NCT01471171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium Bromide
Description: 1 puff of 400 micro grams in the morning (09:00 ± 1h) and in the evening (21:00 ± 1h)
Study NCT01471171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h)
Study NCT00845858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide
Description: 30 minutes before meals and at bedtime for 4 weeks
Study NCT02160821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caudal Epidural
Description: Ultrasound Guided Caudal Block
Study NCT02160821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane Block
Description: Ultrasound Guided Transversus Abdominis Plane Block
Study NCT00845858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 minutes before meals and at bedtime
Study NCT04302896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dolutegravir oral tablet 50mg
Description: Tivicay® (dolutegravir, DTG), a HIV-1 integrase strand transfer inhibitor (INSTI), is FDA-approved in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in pediatric patients weighing at least 30kg. Tivicay® 50mg tablets \[GlaxoSmithKline\] are yellow, round, film-coated, biconvex tablets debossed with SV 572 on one side and 50 on the other side. The inactive ingredients in each tablet are D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate. The tablet film-coating contains the inactive ingredients iron oxide yellow macrogol/PEG, polyvinyl alcohol-part hydrolyzed, talc, and titanium dioxide.
Study NCT04302896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emtricitabine/tenofovir alafenamide oral tablet 200mg/25mg
Description: Descovy® (emtricitabine/tenofovir alafenamide, FTC/TAF) is a combination of two HIV nucleoside analog reverse transcriptase inhibitors (NRTIs) FDA-approved in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35kg. Descovy® 200 mg/25 mg tablets \[Gilead\] are blue, rectangular-shaped, and film-coated with GSI debossed on one side and 225 on the other side. The inactive ingredients are croscarmellose sodium, magnesium stearate, and microcrystalline cellulose. The tablets are film-coated with a coating material containing indigo carmine aluminum lake, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.
Study NCT04302896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir disoproxil fumarate oral tablet 300mg
Description: Viread® (tenofovir DF, TDF) is a nucleotide analog HIV-1 reverse transcriptase inhibitor and a hepatitis B reverse transcriptase inhibitor FDA-approved for the treatment of HIV-1 infection in combination with other antiretroviral agents and for the treatment of chronic hepatitis B in adults and pediatric patients 2 years of age and older weighing at least 10kg. Viread® 300mg tablets \[Gilead\] are almond-shaped, light blue, film-coated tablets containing 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil, are debossed with GILEAD and 4331 on one side and with 300 on the other side. The inactive ingredients in each tablet are croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and pregelatinized starch. Viread® 300mg tablets are coated with Opadry II Y-30-10671-A, which contains FD\&C blue #2 aluminum lake, hypromellose 2910, lactose monohydrate, titanium dioxide, and triacetin.
Study NCT04302896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamivudine oral tablet 300mg
Description: Lamivudine (Epivir®, 3TC) is a nucleoside analogue reverse transcriptase inhibitor FDA-approved in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients at least 3 months of age. Lamivudine 300mg tablets \[Apotex Inc.\] are gray, modified diamond-shaped, film-coated, and engraved with LMV 300 on one side and APO on the reverse side. Inactive ingredients are black iron oxide, colloidal silicon dioxide, crospovidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose anhydrous, magnesium stearate, polyethylene glycol, and titanium dioxide.
Study NCT05253729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused ESWT
Description: F-ESWT (dose 0.01-0.15 mJ/mm2, frequency 4-5 Hz, 1500 shocks) was applied perpendicular to the palmar side of the wrist which was done once a week for a total of three sessions plus conservative treatment.
Study NCT05253729 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants in the control group received only conservative treatment including disease education, advice about proper posture and activity, night wrist splint and nerve gliding exercise.
Study NCT04946383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib plus Quercetin
Description: Dasatinib plus Quercetin
Study NCT04580069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphatic drainage
Description: The interventions follow the validated techniques normally used in international rehabilitation
Study NCT00661349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine
Description: 2 ITIAN (o 1 ITIAN+TDF)+ nevirapine, 2 tablet 200/50 mg to 12 hours
Study NCT03298152 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CERASMART Endocrown
Description: Endocrown fixed restoration used to restore endodontically treated anterior teeth using CERASMART blocks